Nurix Therapeutics, INC Form 4 insider transactions

Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., reported a sale of 8,148 shares of common stock on April 2, 2026, executed under a Rule 10b5-1 trading plan.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock for a weighted average price of $15.4385 under a pre-arranged 10b5-1 trading plan.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, received significant equity awards, including stock options and restricted stock units, as part of his compensation.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, was granted 93,750 stock options and 42,875 restricted stock units.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, was granted 93,750 employee stock options and 42,875 restricted stock units.

Nurix Therapeutics' President and CEO, Arthur T. Sands, was granted 562,500 employee stock options with an exercise price of $16.45.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 14,261 shares of common stock for a weighted average price of $16.6621 per share.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, exercised stock options to acquire 31,333 shares of common stock at $0.84 per share.

Nurix Therapeutics' CFO, Hans van Houte, reported the acquisition of common stock through RSU vesting and subsequent sales to cover tax withholding obligations.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 4,421 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the vesting of restricted stock units and subsequent sale of shares to cover tax withholding obligations.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, exercised stock options and immediately sold the acquired shares as part of a pre-arranged 10b5-1 trading plan.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 37,600 shares of common stock for a weighted average price of $17.0664 after exercising options.

Nurix Therapeutics Director Roger D. Dansey was granted 50,000 stock options with an exercise price of $12.52, vesting monthly over three years.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 6,284 shares of common stock on November 3, 2025, under a pre-arranged trading plan.

Nurix Therapeutics CFO Hans van Houte reported the exercise of restricted stock units and subsequent sale of shares to cover tax withholding obligations.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax withholding purposes.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the vesting of restricted stock units and a subsequent mandatory 'sell to cover' transaction to satisfy tax obligations.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, was granted 20,000 Restricted Stock Units, vesting over two years.

Julia P. Gregory, a Director at Nurix Therapeutics, Inc., exercised options to acquire 10,750 shares of common stock at $1.86 per share.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 5,402 shares of common stock at a weighted average price of $11.0325 per share, executed under a Rule 10b5-1 trading plan.

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, reported the vesting of restricted stock units and a non-discretionary sale of shares to cover tax obligations.

Nurix Therapeutics' Chief Legal Officer, Christine Ring, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction to satisfy tax obligations.

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the acquisition of common stock through RSU vesting and a subsequent sale of shares to cover tax withholding obligations.

Director Paul M. Silva acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025, vesting fully by May 19, 2026, or the next annual meeting.

Director Lori Anne Kunkel reports receiving a stock option grant for 25,000 shares of Nurix Therapeutics, Inc.

Director Julia P. Gregory acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025, vesting fully by May 19, 2026, or the next annual meeting.

Director Edward C. Saltzman acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025.

David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options on May 19, 2025, exercisable at $9.51.